Guidance

References

Updated 17 June 2026

References

1. Gao L, Shi Q, Liu Z, Li Z, Dong X. ‘Impact of the COVID-19 pandemic on malaria control in Africa: a preliminary analysis’ Tropical Medicine and Infectious Disease 2023: volume 8, issue 1, page 67

2. UK Health Security Agency (UKHSA). Malaria imported into the UK 2021 (updated 9 June 2023)

3. General Medical Council. Good Medical Practice London 2011

4. Broderick C, Nadjm B, Smith V, Blaze M, Checkley A, Chiodini PL and others. ‘Clinical, geographical, and temporal risk factors associated with presentation and outcome of vivax malaria imported into the United Kingdom over 27 years: observational study’ British Medical Journal 2015: volume 350, h1,703

5. World Health Organization (WHO). World Malaria Report 2024

6. White N. ‘Malaria’ In: Farrar J and others, editors. Manson’s Tropical Diseases: Elsevier Health Sciences 2024, page 573

7. De Silva PM, Marshall JM. ‘Factors contributing to urban malaria transmission in sub- Saharan Africa: a systematic review’ Journal of Tropical Medicine 2012: 819563

8. Merga H, Degefa T, Birhanu Z, Tadele A, Lee MC, Yan G, Yewhalaw D. ‘Urban malaria in sub-Saharan Africa: a scoping review of epidemiologic studies’ Malaria Journal 2025: volume 24, issue 1, page 131

9. Siswantoro H, Russell B, Ratcliff A, Prasetyorini B, Chalfein F, Marfurt J, Kenangalem E, Wuwung M, Piera KA, Ebsworth EP, Anstey NM, Tjitra E, Price RN. ‘In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia’ Antimicrobial Agents and Chemotherapy 2011: volume 55, issue 1, pages 197 to 202

10. Baird JK. ‘Resistance to therapies for infection by Plasmodium vivax’ Clinical Microbiology Reviews 2009: volume 22, issue 3, pages 508 to 534

11. Ric N Price, Lorenz von Seidlein, Neena Valecha, Francois Nosten, J Kevin Baird, Nicholas J White. ‘Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis’ Lancet Infectious Diseases 2014: volume 14, pages 982 to 991

12. Goodyer LI, Debboun M. ‘Anthropod repellents in public health.’ In Advances in Arthropod Repellents 2022: Academic Press, pages 1 to 18

13. Thrower Y, Goodyer LI. ‘Application of insect repellents by travellers to malaria-endemic areas’ Journal of Travel Medicine 2006: volume 13, pages 198 to 203

14. Hasler T, Fehr J, Held U, Schlagenhauf P. ‘Use of repellents by travellers: a randomised, quantitative analysis of applied dosage and an evaluation of knowledge, attitudes and practices (KAP)’ Travel Medicine and Infectious Disease 2019

15. Chen-Hussey V, Behrens R, Logan JG. ‘Assessment of methods used to determine the safety of the topical insect repellent N, N-diethyl-m-toluamide (DEET)’ Parasites and Vectors 2014: volume 7, issue 1, page 173

16. Murphy ME, Montemarano AD, Debboun M, Gupta R. ‘The effect of sunscreen on the efficacy of insect repellent: a clinical trial’ Journal of the American Academy of Dermatology 2000: volume 43, issue 2, pages 219 to 222

17. Webb CE, Russell RC. ‘Insect repellents and sunscreen: implications for personal protection strategies against mosquito‐borne disease’ Australian and New Zealand Journal of Public Health 2009: volume 33, issue 5, pages 485 to 490

18. Stanczyk NM, Behrens RH, Chen-Hussey V, Stewart SA, Logan JG. ‘Mosquito repellents for travellers’ British Medical Journal 2015: volume 350, h99

19. McGready R, Hamilton KA, Simpson JA, Cho T, Luxemburger C, Edwards R and others. ‘Safety of the insect repellent N, N-diethyl-M-toluamide (DEET) in pregnancy’ The American Journal of Tropical Medicine and Hygiene 2001: volume 65, issue 4, pages 285 to 289

20. United States Environmental Protection Agency. ‘Reregistration Eligibility Decision (RED) DEET’ Prevention, Pesticides and Toxic Substances 1998

21. Govere J, Durrheim D, Baker L, Hunt R, Coetzee M. ‘Efficacy of 3 insect repellents against the malaria vector Anopheles arabiensis’ Medical and Veterinary Entomology 2000: volume 14, issue 4, pages 441 to 444

22. Moore SJ, Darling ST, Sihuincha M and others. ‘A low-cost repellent for malaria vectors in the Americas: results of 2 field trials in Guatemala and Peru’ Malaria Journal 2007: volume 6, page 101

23. Johirul Islam, Kamaruz Zaman, Sanjukta Duarah, Pakalapati Srinivas Raju, Pronobesh Chattopadhyay. ‘Mosquito repellents: an insight into the chronological perspectives and novel discoveries’ Acta Tropica 2017: volume 167, pages 216 to 223

24. Colucci B, Müller P. ‘Evaluation of standard field and laboratory methods to compare protection times of the topical repellents PMD and DEET’ Scientific Reports 2018: volume 8, issue 1, pages 1 to 11

25. BPPD. ‘p-Menthane-3,8-diol (011550) Biopesticide Registration Eligibility Document’

26. Klun J. A, Khirimian A, Debboun M. ‘Repellent and deterrent effects of SS220, Picaridin, and DEET suppress human blood feeding by Aedes aegypti, Anopheles stephensi and Phlebotomus papatasi’ Journal of Medical Entomology 2006: volume 43, issue 1, pages 34 to 39

27. Goodyer L, Schofield S. ‘Mosquito repellents for the traveller: does picaridin provide longer protection than DEET?’ Journal of Travel Medicine 2018: volume 1, issue 25, pages S10 to S15

28. Badolo A, Ilboudo‐Sanogo E, Ouédraogo AP, Costantini C. ‘Evaluation of the sensitivity of Aedes aegypti and Anopheles gambiae complex mosquitoes to 2 insect repellents: DEET and KBR 3023’ Tropical Medicine and International Health 2004: volume 9, issue 3, pages 330 to 334

29. Costantini C, Badolo A, Ilboudo-Sanogo E. ‘Field evaluation of the efficacy and persistence of insect repellents DEET, IR3535, and KBR 3023 against Anopheles gambiae complex and other Afrotropical vector mosquitoes’ Transactions of the Royal Society of Tropical Medicine and Hygiene 2004: volume 98, issue 11, pages 644 to 652

30. WHO. ‘Report of the fourth WHOPES working group meeting. Review of: IR3535, KBR3023,(RS)-methoprene 20% EC, pyriproxyfen 0.5% GR and lambda-cyhalothrin 2.5% CS’ WHO Pesticide Evaluation Scheme (WHOPES) Working Group meeting. 4 to 5 December 2001

31. Anon. ‘Picaridin: a new insect repellent’ The Medical Letter on Drugs and Therapeutics 2005: volume 47, issue 1,210, pages 46 to 47

32. Frances SP. Picaridin. In: Debboun M, Strickman D, Frances SP, editors. ‘Insect Repellents: Principles, Methods, and Uses’ Boca Raton: CRC Press 2007, pages 337 to 440

33. Heng S, Sluydts V, Durnez L and others. ‘Safety of a topical insect repellent (picaridin) during community mass use for malaria control in rural Cambodia’ PLoS One 2017: volume 12, issue 3, pages 1 to 16

34. Frances S. P, Cooper R. D. ‘Personal protection measures against mosquitoes: a brief history and current use of repellents by the Australian defence force’ ADF Health 2002: volume 3, pages 58 to 63

35. Fradin MS, Day JF. ‘Comparative efficacy of insect repellents against mosquito bites’ New England Journal of Medicine 2002: volume 347, issue 1, pages 13 to 18

36. Strickman D. ‘Topical repellent active ingredients in common use’ In: Debboun M, Frances SP, Strickman D, editors. ‘Insect Repellent Handbook (second edition)’ CRC Press Taylor and Francis Group: 2014

37. WHO. ‘Vector control: methods for use by individuals and communities’ Prepared by Jan Rozendaal 1997

38. Petersen E. ‘Malaria chemoprophylaxis: when should we use it and what are the options?’ Expert Review Anti-Infective Therapy 2004: volume 2, pages 119 to 132

39. WHO. ‘Report of the thirteenth WHOPES working group meeting. 28 to 30 July’ 2009

40. Schreck C, Carlson D, Weidhaas D, Posey K, Smith D. ‘Wear and aging tests with permethrin-treated cotton-polyester fabric’ Journal of Economic Entomology 1980: volume 73, issue 3, pages 451 to 453

41. Ross M. Boyce, Bonnie E. Shook-Sa, Ronnie Ndizeye, Emmanuel Baguma, Dana Giandomenico, Caitlin A. Cassidy, Solomon Eshun, and others. ‘Permethrin-Treated Baby Wraps for the Prevention of Malaria’ New England Journal of Medicine 2025

42. Marta F Maia, Merav Kliner, Marty Richardson, Christian Lengeler, Sarah J Moore, Cochrane Infectious Diseases Group. ‘Mosquito repellents for malaria prevention’ Cochrane Database of Systematic Reviews 2018 February: 2018 issue 2, CD011595

43. McCain WC, Leach GJ. ‘Repellents used in fabric: the experience of the US military’ In: M D, SP F, D S, editors. ‘Insect Repellents: Principles, Methods, and Uses’ Boca Raton: CRC Press 2007, pages 261 to 273

44. Hewitt S, Farhan M, Urhaman H, Muhammad N, Kamal M, Rowland M. ‘Self-protection from malaria vectors in Pakistan: an evaluation of popular existing methods and appropriate new techniques in Afghan refugee communities’ Annals of Tropical Medicine and Parasitology 1996: volume 90, issues 3, pages 337 to 344

45. Ives AR, Paskewitz SM. ‘Testing vitamin B as a home remedy against mosquitoes’ Journal of the American Mosquito Control Association 2005: volume 21, issue 2, pages 213 to 217

46. Lefèvre T, Gouagna LC, Dabiré KR, Elguero E, Fontenille D, Renaud F, Costantini C, Thomas F. ‘Beer consumption increases human attractiveness to malaria mosquitoes’ PLoS One 2010 March 4: volume 5, issue 3, article e9546

47. Dondorp A, Newton P, Mayxay M, Van Damme W, Smithuis F, Yeung S and others. ‘Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross‐sectional survey on the prevalence of fake antimalarials’ Tropical Medicine and International Health 2004: volume 9, issue 12, pages 1,241 to 1,246

48. Chulay JD. ‘Challenges in the development of antimalarial drugs with causal prophylactic activity’ Transactions of the Royal Society of Tropical Medicine and Hygiene 1998: volume 92, issue 6, pages 577 to 579

49. Franco-Paredes C, Santos-Preciado JI. ‘Problem pathogens: prevention of malaria in travellers’ The Lancet Infectious Diseases 2006: volume 6, issue 3, pages 139 to 149

50. Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ. ‘Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I’ The American Journal of Tropical Medicine and Hygiene 2006: volume 75, issue 3, pages 402 to 415

51. Hill D. ‘Issues for long-term and expatriate travellers.’ In: Cook GC, editor. ‘Travel- associated disease: papers based on a conference organised by the Royal College of Physicians of London’ Royal College of Physicians 1995: page 101

52. Pappaioanou M, Fishbein DB, Dreesen DW, Schwartz IK, Campbell GH, Sumner JW and others. ‘Antibody response to pre-exposure human diploid-cell rabies vaccine given concurrently with chloroquine’ New England Journal of Medicine 1986: volume 314, issue 5, pages 280 to 284

53. Schlagenhauf P, Adamcova M, Regep L, Schaerer MT, Rhein H-G. ‘The position of mefloquine as a 21st century malaria chemoprophylaxis’ Malaria Journal 2010: volume 9, issue 9, page 357

54. Moore DA, Grant AD, Armstrong M, Stümpfle R, Behrens RH. ‘Risk factors for malaria in UK travellers’ Transactions of the Royal Society of Tropical Medicine and Hygiene 2004: volume 98, issue 1, pages 55 to 63

55. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. ‘Epidemiology of drug-resistant malaria’ The Lancet Infectious Diseases 2002: volume 2, issue 4, pages 209 to 218

56. Schlagenhauf P, Hatz C, Behrens R, Visser L, Funk M, Holzer B and others. ‘Mefloquine at the crossroads? Implications for malaria chemoprophylaxis in Europe’ Travel Medicine and Infectious Disease 2015: volume 13, issue 2, pages 192 to 196

57. Tickell-Painter M, Maayan N, Saunders R, Pace C, Sinclair D. ‘Mefloquine for preventing malaria during travel to endemic areas’ Cochrane Database of Systematic Reviews 2017: volume 10, CD006491

58. Schlagenhauf P, Tschopp A, Johnson R, Nothdurft H, Beck B, Schwartz E and others. ‘Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, 4 arm study’ British Medical Journal 2003: volume 327, issue 7,423, page 1,078

59. Meier CR, Wilcock K, Jick SS. ‘The risk of severe depression, psychosis or panic attacks with prophylactic antimalarials’ Drug safety 2004: volume 27, issue 3, pages 203 to 213

60. Wells TS, Smith TC, Smith B, Wang LZ, Hansen CJ, Reed RJ and others. ‘Mefloquine use and hospitalizations among US service members, 2002 to 2004’ The American Journal of Tropical Medicine and Hygiene 2006: volume 74, issue 5, pages 744 to 749

61. Taylor WRJ, White NJ. ‘Antimalarial drug toxicity: a review’ Drug Safety 2004: volume 27, issue 1, pages 25 to 61

62. Ohrt C, Richie TL, Widjaja H, Shanks GD, Fitriadi J, Fryauff DJ and others. ‘Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers: a randomized, double-blind, placebo-controlled trial’ Annals of Internal Medicine 1997: volume 126, issue 12, pages 963 to 972

63. UK Teratology Information Service (UKTIS). ‘Malaria prophylaxis and treatment in pregnancy’ (updated November 2024; cited 2024)

64. Joint Formulary Committee. British National Formulary. BMJ Group and Pharmaceutical Press 2025 (accessed 4th October 2025)

65. Tan KR, Magill AJ, Parise ME, Arguin PM. ‘Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis’ The American Journal of Tropical Medicine and Hygiene 2011: volume 84, issue 4, pages 517 to 531

66. Bryant SG, Fisher S, Kluge RM. ‘Increased frequency of doxycycline side effects’ Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 1987: volume 7, issue 4, pages 125 to 129

67. Edstein M, Yeo A, Kyle D, Looareesuwan S, Wilairatana P, Rieckmann K. ‘Proguanil polymorphism does not affect the antimalarial activity of proguanil combined with atovaquone in vitro’ Transactions of the Royal Society of Tropical Medicine and Hygiene 1996: volume 90, issue 4, pages 418 to 421

68. Berman J, Nielsen R, Chulay J, Dowler M, Kain K, Kester K and others. ‘Causal prophylactic efficacy of atovaquone-proguanil (MalaroneTM) in a human challenge model’ Transactions of the Royal Society of Tropical Medicine and Hygiene 2001: volume 95, issue 4, pages 429 to 432

69. Marra F, Salzman JR, Ensom MH. ‘Atovaquone–proguanil for prophylaxis and treatment of malaria’ Annals of Pharmacotherapy 2003: volume 37, issue 9, pages 1,266 to 1,275

70. Camus D, Djossou F, Schilthuis HJ, Høgh B, Dutoit E, Malvy D and others. ‘Atovaquone- proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune pediatric travelers: results of an international, randomized, open-label study’ Clinical Infectious Diseases 2004: volume 38, issue 12, pages 1,716 to 1,723

71. Overbosch D, Schilthuis H, Bienzle U, Behrens RH, Kain KC, Clarke PD and others. ‘Atovaquone-proguanil versus mefloquine for malaria prophylaxis in non-immune travelers: results from a randomized, double-blind study’ Clinical Infectious Diseases 2001: 33, issue 7, pages 1,015 to 1,021

72. Shanks GD, Gordon DM, Klotz FW, Aleman GM, Oloo AJ, Sadie D and others. ‘Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria’ Clinical Infectious Diseases 1998: volume 27, issue 3, pages 494 to 449

73. Faucher J-F, Binder R, Missinou MA, Matsiegui P-B, Gruss H, Neubauer R and others. ‘Efficacy of atovaquone/proguanil for malaria prophylaxis in children and its effect on the immunogenicity of live oral typhoid and cholera vaccines’ Clinical Infectious Diseases 2002: volume 35, issue 10, pages 1,147 to 1,154

74. Lell B, Luckner D, Ndjavé M, Scott T, Kremsner PG. ‘Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children’ The Lancet 1998: volume 351, issue 9,104, pages 709 to 713

75. Sukwa T, Mulenga M, Chisdaka N, Roskell N, Scott T. ‘A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia’ The American Journal of Tropical Medicine and Hygiene 1999: volume 60, issue 4, pages 521 to 525

76. Ling J, Baird JK, Fryauff DJ, Sismadi P, Bangs MJ, Lacy M. ‘Randomized, placebo- controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia’ Clinical Infectious Diseases 2002: volume 35, issue 7, pages 825 to 833

77. Nakato H, Vivancos R, Hunter PR. ‘A systematic review and meta-analysis of the effectiveness and safety of atovaquone–proguanil (Malarone) for chemoprophylaxis against malaria’ Journal of Antimicrobial Chemotherapy 2007: volume 60, issue 5, pages 929 to 936

78. Soto J, Toledo J, Luzz M, Gutierrez P, Berman J, Duparc S. ‘Randomized, double-blind, placebo-controlled study of Malarone for malaria prophylaxis in non-immune Colombian soldiers’ The American Journal of Tropical Medicine and Hygiene 2006: volume 75, issue 3, pages 430 to 433

79. Savelkoel J, Binnendijk KH, Spijker R, van Vugt M, Tan K, Hanscheid T and others. ‘Abbreviated atovaquone-proguanil prophylaxis regimens in travellers after leaving malaria-endemic areas: a systematic review’ Travel Medicine and Infectious Diseases 2018: volume 21, pages 3 to 20

80. Pasternak B, Hviid A. ‘Atovaquone-proguanil use in early pregnancy and the risk of birth defects’ Archives of Internal Medicine 2011: volume 171, issue 3, pages 259 to 260

81. Tan KR, Fairley JK, Wang M, Gutman JR. ‘A survey on outcomes of accidental atovaquone-proguanil exposure in pregnancy’ Malaria Journal 2018: volume 17, issue 1, page 198

82. Ferrara P, Masuet-Aumatell C, Aguero F, Ramon-Torrell JM. ‘The use of stand-by emergency treatment (SBET) for malaria in travellers: a systematic review and meta- analysis of observational studies’ Journal of Infection 2018

83. Franken DJ, Jongen VW, Rooyakkers A, Grobusch MP, Elsinga J, Boering M, Prins M, van Cleef BAGL. ‘Adherence to stand-by emergency treatment and mosquito protection measures in short-term travellers to moderate malaria risk areas’ New Microbes and New Infections 2025: volume 1, issue 63, page 101561

84. Schlagenhauf P, Petersen E. ‘Standby emergency treatment of malaria in travelers: experience to date and new developments’ Expert Review of Anti-infective Therapy 2012: volume 10, issue 5, pages 537 to 546

85. WHO. ‘Malaria 2015 online update’ In: World Health Organization, editor. International Travel and Health, 2012

86. Touze J, Heno P, Fourcade L, Deharo J, Thomas G, Bohan S and others. ‘The effects of antimalarial drugs on ventricular repolarization’ The American Journal of Tropical Medicine and Hygiene 2002: volume 67, issue 1, pages 54 to 60

87. Rogers CL, Bain BJ, Garg M, Fernandes S, Mooney C, Chiodini PL, British Society for Haematology. ‘British Society for Haematology guidelines for the laboratory diagnosis of malaria’ British Journal of Haematology 2022: volume 197, issue 3, pages 271 to 282

88. Berthod D, Rochat J, Voumard R, Rochat L, Genton B, D’Acremont V. ‘Self-diagnosis of malaria by travellers: a cohort study on the use of malaria rapid diagnostic tests provided by a Swiss travel clinic’ Malaria Journal 2017: volume 16, issue 1, page 436

89. WHO. ‘The use of malaria rapid diagnostic tests (second edition)’ 2006

90. Jelinek T, Grobusch M, Nothdurft H. ‘Use of dipstick tests for the rapid diagnosis of malaria in non-immune travelers’ Journal of Travel Medicine 2000: volume 7, issue 4, pages 175 to 179

91. Chiodini PL, Bowers K, Jorgensen P, Barnwell JW, Grady KK, Luchavez J and others. ‘The heat stability of Plasmodium lactate dehydrogenase-based and histidine-rich protein 2-based malaria rapid diagnostic tests’ Transactions of the Royal Society of Tropical Medicine and Hygiene 2007: volume 101, issue 4, pages 331 to 337

92. Maltha J, Gillet P, Heutmekers M, Bottieau E, Van Gompel A, Jacobs J. ‘Self-diagnosis of malaria by travelers and expatriates: assessment of malaria rapid diagnostic tests available on the internet’ PLoS One 2013: volume 8, issue 1, article e53102

93. UKHSA. ‘Notifications of infectious diseases (NOIDs)’ (Notifications about suspected infectious diseases, collected by UKHSA)

94. Schlagenhauf P, Blumentals WA, Suter P, Regep L, Vital-Durand G, Schaerer MT and others. ‘Pregnancy and fetal outcomes after exposure to mefloquine in the pre-and periconception period and during pregnancy’ Clinical Infectious Diseases 2012: volume 54, issue 11, pages e124 to e31

95. Roggelin L, Cramer JP. ‘Malaria prevention in the pregnant traveller: a review’ Travel Medicine and Infectious Diseases 2014: volume 12, issue 3, pages 229 to 236

96. Mayer RC, Tan KR, Gutman JR. ‘Safety of atovaquone-proguanil during pregnancy’ Journal of Travel Medicine 2019, June 1: volume 26, issue 4, page tay138

97. Andrejko KL, Mayer RC, Kovacs S, Slutsker E, Bartlett E, Tan KR, Gutman JR. ‘The safety of atovaquone-proguanil for the prevention and treatment of malaria in pregnancy: a systematic review’ Travel Medicine and Infectious Disease 2019 January to February: volume 27, pages 20 to 26

98. Gutman JR, Hall C, Khodr ZG, Bukowinski AT, Gumbs GR, Conlin A-M S, Wells NY, Tan KR. ‘Atovaquone-proguanil exposure in pregnancy and risk for adverse fetal and infant outcomes: a retrospective analysis’ Travel Medicine and Infectious Disease 2019: volume 32

99. McKinney KL, Wu HM, Tan KR, Gutman JR. ‘Malaria in the pregnant traveler’ Journal of Travel Medicine 2020 July: volume 27, issue 4

100. Armstrong G, Beg M, Scahill S, Jassal S. ‘Warfarin potentiated by proguanil’ British Medical Journal 1991: volume 303, issue 6,805, page 789

101. Leon MN, Lateef M, Fuentes F. ‘Prevention and management of cardiovascular events during travel’ Oxford UK 1996, pages 227 to 230

102. Ringwald J, Strobel J, Eckstein R. ‘Travel and oral anticoagulation’ Journal of Travel Medicine 2009: volume 16, issue 4, pages 276 to 283

103. Khalife R, Burnett AE, Tritschler T, Waldron B, Xu Y. ‘Practical Prescribing: Direct oral anticoagulants’ BMJ (Clinical Research edition) 2024: volume 386, article e079520

104. Tripodi A, Marchetti M, Scalambrino E. ‘Direct oral anticoagulants measurement: when is it necessary?’ Trasfusione del Sangue 2025: volume 23, issue 1, pages 55 to 58

105. Ringwald J, Grauer M, Eckstein R, Jelinek T. ‘The place of new oral anticoagulants in travel medicine’ Travel Medicine and Infectious Disease 2014: volume 12, issue 1, pages 7 to 19

106. Saunders MA, Hammer MF, Nachman MW. ‘Nucleotide variability at G6pd and the signature of malarial selection in humans’ Genetics 2002: volume 162, issue 4, pages 1,849 to 1,861

107. Kane M. Chloroquine Therapy and G6PD Genotype 2023 May 16. In: Pratt VM, Scott SA, Pirmohamed M, and others, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-

108. Serjeant GR. ‘Infections in sickle cell disease’ In: Cohen J, Powderly W, editors. ‘Infectious Diseases’ Edinburgh: Mosby 2004, page 1,618

109. Kotton CN, Ryan ET, Fishman JA. ‘Prevention of infection in adult travelers after solid organ transplantation’ American Journal of Transplantation 2005: volume 5, issue 1, pages 8 to 14

110. Kamya MR, Gasasira AF, Yeka A, Bakyaita N, Nsobya SL, Francis D and others. ‘Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study’ Journal of Infectious Diseases 2006: volume 193, issue 1, pages 9 to 15

111. Korenromp EL, Williams BG, De Vlas SJ, Gouws E, Gilks CF, Ghys PD and others. ‘Malaria attributable to the HIV-1 epidemic, sub-Saharan Africa’ Emerging Infectious Diseases 2005: volume 11, issue 9, pages 1,410 to 1,419

112. Mahittikorn A, Kotepui KU, De Jesus Milanez G, Masangkay FR, Kotepui M. ‘A meta- analysis on the prevalence and characteristics of severe malaria in patients with Plasmodium spp. and HIV co-infection’ Science Reports 2021: volume 11, issue1, page 16,655

113. Mouala C, Houzé S, Guiguet M, Abboud P, Pialoux G, Viget N and others. ‘Imported malaria in HIV-infected patients enrolled in the ANRS CO4 FHDH study’ Journal of Acquired Immune Deficiency Syndrome 2008: volume 49, issue 1, pages 55 to 60

114. Mirzohreh ST, Safarpour H, Pagheh AS, Bangoura B, Barac A, Ahmadpour E. ‘Malaria prevalence in HIV-positive children, pregnant women, and adults: a systematic review and meta-analysis’ Parasites and Vectors 2022: volume 15, issue 1, page 324

115. ‘Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV’ (accessed 27 August 2023)

116. Guerra CVC, da Silva BM, Müller P, Baia-da-Silva DC, Moura MAS, Araújo JDA, Silva JCSE, Silva-Neto AV, da Silva Balieiro AA, da Costa-Martins AG, Melo GC, Val F, Bassat Q, Nakaya HI, Martinez-Espinosa FE, Lacerda M, Sampaio VS, Monteiro W. ‘HIV infection increases the risk of acquiring Plasmodium vivax malaria: a 4-year cohort study in the Brazilian Amazon HIV and risk of vivax malaria’ Scientific Reports 2022: volume 12, issue 1, page 9,076

117. Public Health England (PHE). ‘Travelling overseas to visit friends and relatives? 2015’ (updated 28 May 2015)

118. Del Prete V, Mateo-Urdiales A, Bueno-Cavanillas A, Ferrara P. ‘Malaria prevention in the older traveller: a systematic review’ Journal of Travel Medicine October 2019: volume 26, issue 7

119. Health Protection Agency (HPA). ‘Migrant Health: Infectious diseases in non-UK born populations in England, Wales and Northern Ireland: a baseline report, 2006’

120. HPA. ‘Migrant Health: infectious diseases in non-UK born populations in England, Wales, and Northern Ireland. An update to the baseline report, 2011’

121. PHE. ‘Migrant Health Guide 2014’ (updated 14 July 2014)

122. World Malaria Report 2023

123. Walz EJ, Volkman HR, Adedimeji AA, Abella J, Scott LA, Angelo KM and others. ‘Barriers to malaria prevention in US-based travelers visiting friends and relatives abroad: a qualitative study of West African immigrant travelers’ Journal of Travel Medicine 2019: volume 26, issue 2

124. Morgan M, Figueroa-Muñoz JI. ‘Barriers to uptake and adherence with malaria prophylaxis by the African community in London, England: focus group study’ Ethnicity and Health 2005: volume 10, issue 4, pages 355 and 372. pmid:16191732

125. Neave PE, Behrens RH, Jones COH. ‘“You’re losing your Ghanaianess”: understanding malaria decision-making among Africans visiting friends and relatives in the UK’ Malaria Journal 2014: volume 13, issue 1, page 287

126. Walz EJ, Wanduragala D, Adedimeji AA, Volkman HR, Gaines J, Angelo KM, Boumi AE, Coyle C, Dunlop SJ, Stauffer WM. ‘Community-based participatory research in travel medicine to identify barriers to preventing malaria in VFR travellers’ Journal of Travel Medicine January 2019: volume 26, issue 1

127. Stenbeck J. ‘Health hazards in Swedish field personnel in the tropics’ Travel Medicine International 1991: volume 9: pages 51 to 59

128. Schneider I, Bradley D. ‘Unpublished work’ 2003

129. Steffen R, Heusser R, Mächler R, Bruppacher R, Naef U, Chen D and others. ‘Malaria chemoprophylaxis among European tourists in tropical Africa: use, adverse reactions, and efficacy’

130. Janosi M. ‘Advice to long-term travellers’ Travel Medicine International 1998: volume 6, pages 110 to 112

131. Lobel HO, Phillips-Howard PA, Brandling-Bennett A, Steffen R, Campbell CC, Huong A and others. ‘Malaria incidence and prevention among European and North American travellers to Kenya’ Bulletin of the WHO 1990: volume 68, issue 2, page 209

132. Peragallo MS, Sabatinelli G, Sarnicola G. ‘Compliance and tolerability of mefloquine and chloroquine plus proguanil for long-term malaria chemoprophylaxis in groups at particular risk (the military)’ Transactions of the Royal Society of Tropical Medicine and Hygiene 1999: volume 93, issue 1, pages 73 to 77

133. Buma APH, Thiel PPv, Lobel HO, Ohrt C, Ameijden EJv, Veltink RL and others. ‘Long- term malaria chemoprophylaxis with mefloquine in Dutch marines in Cambodia’ Journal of Infectious Diseases 1996: volume 173, issue 6, pages 1,506 to 1,509

134. Lobel HO, Miani M, Eng T, Bernard KW, Hightower AH, Campbell CC. ‘Long-term malaria prophylaxis with weekly mefloquine’ The Lancet 1993: volume 341, issue 8,849, pages 848 to 851

135. WHO (2015). ‘Malaria: factsheet number 94’ (updated April 2015)

136. Hughes C, Tucker R, Bannister B, Bradley D. ‘Malaria prophylaxis for long-term travellers’ Communicable Disease and Public Health 2003: volume 6, issue 3, pages 200 to 208

137. Luzzi GA, Peto TE. ‘Adverse effects of antimalarials’ Drug Safety 1993: volume 8, issue 4, pages 295 to 311

138. Lange WR, Frankenfield DL, Moriarty-Sheehan M, Contoreggi CS, Frame JD. ‘No evidence for chloroquine-associated retinopathy among missionaries on long-term malaria chemoprophylaxis’ The American Journal of Tropical Medicine and Hygiene 1994: volume 51, issue 4, pages 389 to 392

139. Overbosch D. ‘Post‐marketing surveillance: adverse events during long‐term use of Atovaquone/Proguanil for travelers to malaria‐endemic countries’ Journal of Travel Medicine 2003: volume 10, volume s1, pages S16 to S20

140. Cathcart S, Lawrence J, Grant A, Quinn D, Whitty C, Jones J and others. ‘Estimating unreported malaria cases in England: a capture–recapture study’ Epidemiology and Infection 2010: volume 138, issue 7, pages 1,052 to 1,058